

AD \_\_\_\_\_

AWARD NUMBER: W81XWH-09-1-0120

TITLE: Pilot study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) In Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas

PRINCIPAL INVESTIGATOR: Kent Robertson, M.D., Ph.D.

CONTRACTING ORGANIZATION: Indiana University  
Indianapolis, IN 46202

REPORT DATE: July 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> July 2013		<b>2. REPORT TYPE</b> Annual	<b>3. DATES COVERED</b> 1 April 2013 – 30 June 2013		
<b>4. TITLE AND SUBTITLE</b>  Pilot study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) In Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas			<b>5a. CONTRACT NUMBER</b>		
			<b>5b. GRANT NUMBER</b> W81XWH-09-1-0120		
			<b>5c. PROGRAM ELEMENT NUMBER</b>		
<b>6. AUTHOR(S)</b>  Kent Robertson, M.D., Ph.D. Melissa Lee, CCRP  Email: krobert@iu.edu			<b>5d. PROJECT NUMBER</b>		
			<b>5e. TASK NUMBER</b>		
			<b>5f. WORK UNIT NUMBER</b>		
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Indiana University Indianapolis, IN 46202			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>		
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>		
			<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>		
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>  Please see next page.					
<b>15. SUBJECT TERMS</b> Neurofibromatosis, Gleevec					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>USAMRMC</b>
U	U	U	UU	6	<b>19b. TELEPHONE NUMBER</b> (include area code)

The protocol was submitted to the Indiana University Cancer Center Scientific Review board on July 31, 2009. The Scientific Review board approved the protocol on Oct 7, 2009. The protocol was also submitted to the Indiana University Institutional Review Board on July 31, 2009 and we received final approval 10/29/2009. These documents were submitted to the DOD on 11/2009. We received the DOD provisions on 1/19/2010 and returned the response to the provisions on 2/18/2010. The protocol was amended to include the provisions from the DOD and Novartis and submitted to our IRB 3/16/2010. We received IRB approval of Amendment #1 on 3/29/2010. We received final DOD approval 6/4/2010. We enrolled our first subject on 6/30/2010. We have enrolled 19 patients to date. We amended the study to include pediatric patients. We have requested and received a no-cost extension to complete enrollment of the pediatric cohort. The last patient is scheduled to be enrolled on 9/27/2013

## TABLE of CONTENTS

Introduction	page 2
Key Research Accomplishments	page 2
Reportable Outcomes	page 2
Conclusion	page 3
References	NA
Appendices	NA

**Section I - Introduction of research**

The goal of this Pilot Study is to trial multiple techniques for determining the response of NF1 patients with plexiform neurofibromas to Gleevec® therapy for use in subsequent clinical trials. The impact of this proposal is having a better way to measure/quantify the response of plexiform neurofibromas in NF1 patients to treatment.

**Section II – Body (Progress to date)**

The protocol was submitted to the Indiana University Cancer Center Scientific Review board on July 31, 2009. The Scientific Review board approved the protocol on Oct 7, 2009. The protocol was also submitted to the Indiana University Institutional Review Board on July 31, 2009 and we received final approval 10/29/2009. These documents were submitted to the DOD on 11/2009. We received the DOD provisions on 1/19/2010 and returned the response to the provisions on 2/18/2010. The protocol was amended to include the provisions from the DOD and Novartis and submitted to our IRB 3/16/2010. We received IRB approval of Amendment #1 on 3/29/2010. At this time we are waiting on HRPO approval from Dr. Widemann at the NCI who is a coinvestigator on this trial. This is the final item requested by DOD. We received final DOD approval 6/4/2010 . We enrolled our first subject on 6/30/2010. We have enrolled 19 patients to date. We amended the study to include pediatric patients. We have requested and received a no-cost extension to complete enrollment of the pediatric cohort. The last patient is scheduled to enroll on 9/27/2013

**Section III – Key Research Accomplishments/Reportable outcomes**

No data available at this time.

**Section IV – Conclusions**

No data available at this time. Data continues to be collected and will be analyzed upon completion of accrual and completion of treatment for the 6 month time point.

*Report is to be submitted via email to the following addresses:*

[Iddil.bekirov@us.army.mil](mailto:Iddil.bekirov@us.army.mil)

[jessica.shives@amedd.army.mil](mailto:jessica.shives@amedd.army.mil)

*(Subject line of email USAMRAAGrant/Cooperative award # W81xwh-09-1-0120)*